Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

Yearbook of Medicine ◽

10.1016/s0084-3873(08)70398-5 ◽

2006 ◽

Vol 2006 ◽

pp. 133-134

Author(s):

N.H. Hanna

Keyword(s):

Lung Cancer ◽

Egfr Mutations ◽

Apoptotic Pathways

Download Full-text

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70158-1 ◽

2006 ◽

Vol 2006 ◽

pp. 224-225

Author(s):

N.H. Hanna

Keyword(s):

Lung Cancer ◽

Egfr Mutations ◽

Apoptotic Pathways

Download Full-text

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

Science ◽

10.1126/science.1101637 ◽

2004 ◽

Vol 305 (5687) ◽

pp. 1163-1167 ◽

Cited By ~ 1175

Author(s):

R. Sordella

Keyword(s):

Lung Cancer ◽

Egfr Mutations ◽

Apoptotic Pathways

Download Full-text

Faculty Opinions recommendation of Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1020802.239465 ◽

2004 ◽

Author(s):

Mark Lemmon

Keyword(s):

Lung Cancer ◽

Egfr Mutations ◽

Apoptotic Pathways

Download Full-text

Clinical validation of a sensitive real-time PCR assay for detecting EGFR mutations in plasma ctDNA from patients with non-small cell lung cancer

10.26226/morressier.5b4709856f4cb300109519aa ◽

2018 ◽

Author(s):

Guanshan Zhu

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Real Time ◽

Cell Lung Cancer ◽

Real Time Pcr ◽

Egfr Mutations ◽

Clinical Validation ◽

Small Cell Lung ◽

Download Full-text

Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.

Case Medical Research ◽

10.31525/ct1-nct03992885 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Clinical Study ◽

Combination Therapy ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Egfr Mutations ◽

Small Cell Lung

Download Full-text

Faculty Opinions recommendation of EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1016183.258643 ◽

2004 ◽

Author(s):

Charles Brenner

Keyword(s):

Lung Cancer ◽

Clinical Response ◽

Download Full-text

Faculty Opinions recommendation of EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1016183.222430 ◽

2004 ◽

Author(s):

Charles Streuli

Keyword(s):

Lung Cancer ◽

Clinical Response ◽

Download Full-text

Faculty Opinions recommendation of EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1016183.217465 ◽

2004 ◽

Author(s):

Joachim Herz

Keyword(s):

Lung Cancer ◽

Clinical Response ◽

Download Full-text

Faculty Opinions recommendation of EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1016183.14725081 ◽

2011 ◽

Author(s):

Ruth Palmer

Keyword(s):

Lung Cancer ◽

Clinical Response ◽

Download Full-text

Faculty Opinions recommendation of Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718033874.793480953 ◽

2013 ◽

Author(s):

Nico van Zandwijk

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Egfr Mutations ◽

Small Cell Lung ◽

Download Full-text